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Autoantibodies to myeloperoxidase (MPO) are
present in serafrom patients with variousforms
of vasculitis-associated glomerulonephritis. Evi-
dencefor apathogenic role ofanti-MPO antibod-
ies has been provided mainly by in vitro studies.
We studied thepathogenic role ofautoantibodies
to MPO in a rat model ofmild immune-mediated
glomerular injury. Brown Norway rats were im-
munized with human MPO in complete Freund's
adjuvant or with complete Freund's adjuvant
alone. At 2 weeks after immunization, rats had
developed antibodies to human and rat MPO as
detected by indirect immunofluorescence, en-
zyme-linked immunosorbent assay, and immuno-
precipitation. At this time point, rats were intra-
venously injected with a subnephritogenic dose
of 150 pg of rabbit anti-rat GBM. Rats were sac-
rificed at 4 hours, 24 hours, 4 days, and 10 days
after antibody administration. Control immu-
nized rats developed mild glomerulonephritis
characterized by slight proteinuria at day 10
(14.8 + 8.1 mg/24 hours) and moderate intraglo-
merular accumulation of EDI + macrophages.
Crescent formation, tuft necrosis, and tubular
atrophy were not observed in those rats. In con-
trast, rats immunized with MPO developed se-
vere glomerulonephritis characterized by the
early occurrence of severe hematuria, marked
proteinuria at day 10 (76.2 ± 18.2 mg/24 hours),
and massive glomerular deposition of fibrin.
Complement and rat IgG were present in insuda-
tive lesions, but no linear pattern along the glo-
merular capiUary waU was observed. By light
microscopy, severe glomerular lesions were
found at day 10 consisting ofcrescentformation
andfibrinoid necrosis of capiUary loops. In the
interstitium, tubular necrosis and atrophy and
marked interstitial mononuclear infiltration
were found. In conclusion, autoantibodies to
MPO severely aggravate subclinical anti-GBM
disease demonstrating their in vivo pathogenic
potential. (AmJ Pathol 1996, 149:1695-1 706)
Necrotizing crescentic glomerulonephritis (NCGN)
associated with anti-neutrophil cytoplasmic antibod-
ies (ANCAs) is a rapidly progressive glomerular dis-
ease characterized by segmental fibrinoid necrosis
of the glomerular capillary wall, marked infiltration of
neutrophils and mononuclear cells, and paucity of
IgG deposits.1,2 Autoantibodies in ANCA-associated
NCGN are directed against either proteinase 3 or
myeloperoxidase (MPO), both myeloid lysosomal en-
zymes.3 6 Interestingly, ANCAs have also been de-
tected in 30 to 40% of patients with anti-glomerular
basement membrane (anti-GBM) disease.7-9 In
some of these patients, clinical and pathological
data suggest associated systemic vasculitis.7 The
strong association between pauci-immune NCGN
and ANCAs suggests that ANCAs play a pathogenic
role in this disease. Evidence supporting this hypoth-
esis has been provided mainly by in vitro studies.
These studies have shown that ANCAs can activate
tumor-necrosis-factor-a-primed neutrophils leading
to the production of reactive oxygen species and
cytokines and the release of lysosomal en-
zymes.10-13 Furthermore, it has been demonstrated
that ANCAs can promote the adhesion of neutrophils
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to monolayers of cultured endothelial cells and that
primed neutrophils in the presence of ANCAs induce
lysis of endothelial cells.14-17 So far, the in vivo rele-
vance of these phenomena is not clear.
In a recent study, we hypothesized that NCGN
may develop after focal degranulation and produc-
tion of H202 by activated polymorphonuclear leuko-
cytes (PMNs) in the presence of anti-MPO antibod-
ies.18 This hypothesis was tested by perfusion of a
human lysosomal enzyme extract and H202 into the
kidney of Brown Norway rats previously immunized
with human (h)MPO.19 These rats were found to de-
velop a proliferative NCGN closely resembling hu-
man NCGN. The relevance of this animal model for
human disease is, however, hampered by its use of
heterologous MPO and the necessity to perfuse the
kidneys. In the present study, we evaluated whether
a MPO-directed autoimmune response in Brown
Norway rats is able to aggravate subclinical anti-
GBM disease. These studies would provide more
evidence for the pathogenic potential of anti-MPO
antibodies in this and perhaps other types of im-
mune-mediated renal diseases.
Materials and Methods
Animals
All experiments were performed in conventionally
housed, 3-month-old Brown Norway rats (Harlan,
Bilthoven, The Netherlands). Animals were fed ad
libitum with standard chow (Hope Farms, Woerden,
The Netherlands).
Isolation of Human Myeloperoxidase
hMPO was isolated as described before.18 Briefly,
isolated human PMNs were dissolved in cetylmethyl
ammonium chloride (Sigma Chemical Co., St. Louis,
MO) and sonicated. The extract was absorbed to a
concanavalin A Sepharose gel (Pharmacia, Upp-
sala, Sweden) and eluted with methyl-D-mannoside
(Sigma). The eluate was further purified on a Seph-
adex G100 gel (Pharmacia). The final hMPO prepa-
ration had an optical density (OD) 428/280 ratio of
0.85, measured as the ratio between the OD at 428
nm (showing a specific spectral band for MPO) and
the OD obtained at 280 nm. The preparation was not
contaminated with proteinase 3, elastase, or lacto-
ferrin as estimated by antigen-specific enzyme-
linked immunosorbent assay (ELISA), and analysis
by gel electrophoresis showed specific bands for
hMPO (at 15, 38, and 58 kd; data not shown).
Isolation of Rat Myeloperoxidase
Rat MPO was purified from peritoneal exudate cells
(PECs). These PEC suspensions were obtained from
the peritoneal cavity of Brown Norway rats 16 hours
after an intraperitoneal injection of 7 ml of saline with
10% proteose peptone (Difco, Detroit, Ml) and 0.8%
heart infusion broth. Cell suspensions were har-
vested by washing the peritoneal cavity with phos-
phate-buffered saline (PBS) and contained more
then 90% PMNs as judged by morphological criteria.
Rat MPO was purified from the PEC suspension as
described for hMPO.
Immunization
Brown Norway rats were immunized with hMPO in
complete Freund's adjuvant supplemented with 5
mg/ml H37RA (Difco). Rats received 10 ,ug of hMPO
or control solution (sodium acetate buffer) without
hMPO subcutaneously in 0.2 ml at two sites near the
base of the tail.
Detection ofAnti-Human MPO and Anti-Rat
MPO Antibodies by ELISA
Microtiter plates (Greiner, Kremsmunster, Austria)
were coated for 2 hours at 370C with hMPO or rat
MPO at a protein concentration of 2 jig/ml in 0.1
mol/L carbonate buffer, pH 9.6. Plates were incu-
bated with rat serum, diluted in 0.05 mol/L Tris/HCI,
0.05% Tween-20, 1% normal goat serum, 2% bovine
serum albumin, and 0.3 mol/L NaCI, pH 8.0, starting
at a dilution of 1:100 for hMPO and 1:25 for rat MPO.
Antibody binding was detected with alkaline-phos-
phatase-labeled goat anti-rat Ig (Cappel Laborato-
ries, West Chester, PA) followed by p-nitrophenyl
phosphate disodium as a substrate. The plates were
read at 405 nm, and a standard curve was prepared
from a reference serum. Antibody titers were com-
puted from the linearized titration curve of the refer-
ence serum. The antibody titer of the reference se-
rum was set at 100 U.
Detection ofAnti-Human MPO and Anti-Rat
MPO Antibodies by Immunofluorescence
Antibodies to hMPO and rat MPO were detected by
indirect immunofluorescence on ethanol-fixed hu-
man granulocytes or cytospin preparations of rat
PECs. Rat plasma was diluted 1:10, and fluorescein
isothiocyanate (FITC)-labeled rabbit anti-rat IgG
(Cappel) was used to detect bound antibodies.
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Detection ofAnti-Rat MPO Antibodies by
Immunoprecipitation
PECs were obtained as described above. A crude
extract was prepared by nitrogen cavitation and
ureum extraction in the presence of protease inhib-
itors. Nuclei and membrane fragments were dis-
carded by centrifugation. The antigens were labeled
with 1251 by the iodogen method and diluted in PBS
containing 4% bovine serum albumin, 1% Triton
X-100, 0.5% sodium dodecyl sulfate, and 0.5 mol/L
NaCI (immunoprecipitation buffer). Antibody-bound
antigen complexes were precipitated with protein A
CL-4B (Pharmacia), 5 mg per plasma sample,
washed with immunoprecipitation buffer, PBS, and
10 mmol/L Tris/HCI, pH 6.8, and centrifuged through
a sucrose gradient. The samples were boiled for 1
minute in f3-mercaptoethanol/SDS and run on a
12.5% SDS-polyacrylamide gel. After electrophore-
sis, gels were vacuum dried and exposed to a Kodak
XAR5 film.
Induction ofAnti-GBM Nephritis
Antiserum against rat GBM was raised in rabbits as
follows. Rat glomeruli were purified from renal cortex
tissue by a sieving technique.20 Subsequently,
GBMs were isolated from the glomeruli by the deter-
gent method.21 Rabbits were immunized with 1 mg
of rat GBM in complete Freund's adjuvant by multiple
subcutaneous injections and boosted at 1-month in-
tervals with 1 mg of rat GBM in incomplete Freund's
adjuvant. Antibody titers were controlled by immu-
nofluorescence. IgG was purified from serum by am-
monium sulfate precipitation followed by protein A
Sepharose affinity chromatography. At 2 weeks after
immunization with hMPO, rats received a subnephri-
togenic dose of 150 ,ug of anti-GBM antibodies in-
travenously in 1 ml of PBS. Radiolabel experiments
showed that equal amounts of rabbit IgG bound in
the kidney of MPO-immunized and control immu-
nized rats (2.9 ± 0.6 ,ug/g of kidney (n = 3) versus
3.0 ± 0.4 ,ug/g of kidney (n = 3)). For estimation of
proteinuria and hematuria, urine was collected in
metabolic cages during 24 hours after the anti-GBM
injection and before the day of sacrifice at 4 and 10
days. The protein content was measured with the
biuret method. Hematuria was evaluated with the
Sangur test (Boehringer Mannheim, Mannheim, Ger-
many) and graded according to the following scale:
0, absent; 1, mild; 2, intermediate; 3, severe. When
maximal hematuria was found, urine samples were
diluted 10 times in physiological saline and tested
again. The resultant score was then multiplied by 1 0.
Finally, a hematuria score was calculated for each
experimental group at each time point by the sum of
the individual scores of the rats divided by the num-
ber of rats.
Histopathology
At the times indicated, kidneys were perfused with
PBS at 40C to remove the blood. Tissue samples
from the left and right kidney were obtained and
prepared for light microscopy, immunofluorescence,
and immunohistochemistry. For light microscopy, re-
nal tissue was fixed in 2% paraformaldehyde/PBS
and embedded in glycomethacrylate (Technovit
8100 solution, Kulzer, Wehrheim, Germany) as de-
scribed.22 The 2-,um sections were cut and stained
with periodic acid-Schiff and periodic acid silver
methamine. The percentage of crescentic glomeruli
was estimated by examination of 50 glomeruli on
periodic acid-Schiff-stained plastic sections and
counting the number of crescentic glomeruli. For
immunofluorescence, tissue samples were snap fro-
zen in isopentane. The 4-,um sections were fixed in
acetone and then preincubated with normal serum
from the same species as the conjugate. Detection
of rabbit IgG, rat IgG, complement, and fibrin was
tested by immunofluorescence using FITC-labeled
F(ab)2 goat anti-rabbit IgG, F(ab)2 goat anti-rat IgG,
FITC-labeled F(ab)2 goat anti-rat C3, and goat anti-
rat fibrinogen (all from Cappel). As a conjugate,
FITC-labeled F(ab)2 rabbit anti-goat was used (Cap-
pel). The amount of rabbit IgG, rat IgG, and comple-
ment was scored on a semiquantitative scale as
follows: 0, absent; 1, weak; 2, mild; 3, intermediate;
4, strong. Fibrin deposition was evaluated by scoring
the extent of fibrin depositions in 50 glomeruli per rat
according to the following scale: 0, absent; 1, less
than 25%; 2, between 25 and 50%; 3, between 50
and 75%, and 4, between 75 and 100% of the total
glomerular area. The fibrin score per rat was ex-
pressed as the sum of the individual glomerular
scores.
PMNs, monocytes, and T cells were detected by
an immunoperoxidase staining using the monoclonal
antibodies His48 (PMNs23), ED1 (monocytes; Sero-
tec, Oxford, UK), and R73 (T cells24), followed by
peroxidase-labeled rabbit anti-mouse (Dakopatts,
Glostrup, Denmark) and aminoethylcarbimazole as a
substrate. Endogenous peroxidase activity was
blocked with 0.05% H202 in PBS. Sections were
counterstained with hematoxylin. Glomerular infil-
trates were estimated by scoring the number of
His48-, EDl-, and R73-positive cells within 50 glo-
meruli and dividing the total by 50. Interstitial infil-
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trates were quantified on a semiquantitative scale: 0,
absent; 1, minimal; 2, mild; 3, moderate; 4, severe.
Glomerular Presence of Rat MPO
The presence of rat MPO was studied on plastic-
embedded sections for optimal morphological detail.
Dried 2-gm sections were fixed with acetone-buff-
ered formalin (9%) according to Pryzwansky to pre-
vent artifactual shifting of highly cationic MPO.25'26
To study the possible extracellular localization of rat
MPO we applied double-labeling immunofluores-
cence using CD1 lb as a leukocyte marker. For this
purpose, sections were preincubated with 10% goat
serum, followed by a mixture of mouse anti-rat
CD1 lb (OX 42) and biotinylated rabbit anti-rat MPO
for 2 hours at 370C. This was followed by incubation
with a mixture of tetraethylrhodamine-isothiocyanate-
labeled goat anti-mouse IgG (Southern Biotechnol-
ogy Associates, Birmingham, AL) and FITC-labeled
streptavidin (Dakopatts) supplemented with 1% nor-
mal rat serum. Sections were mounted in Citifluor
(Fenwall Laboratories, London, UK). Controls in-
cluded the omission of biotinylated rabbit anti-rat
MPO or OX 42 or both and incubating biotinylated
rabbit anti-rat MPO or OX 42 with the second step
used for the other antibody in the double staining.
Statistical Analysis
Values were expressed as mean ± SD and were
analyzed for statistical differences by the two-tailed
Mann-Whitney U test. Probability values of <0.05
were considered significant.
Experimental Design
Two experimental groups were formed. In the first
group, hMPO-immunized rats received an injection
of a subnephritogenic dose of rabbit anti-rat GBM.
Rats were sacrificed at 4 hours (n = 3), 24 hours (n =
4), 4 days (n = 5), and 10 days (n = 5). In the second
group, control immunized rats received an injection
of a subnephritogenic dose of rabbit anti-rat GBM.
Rats were sacrificed at 4 hours (n = 4), 24 hours (n =
5), 4 days (n = 4), and 10 days (n = 4).
Results
Immune Response to Human and Rat MPO
Brown Norway rats immunized with hMPO devel-
oped antibodies reacting with human and rat MPO
as detected by indirect immunofluorescence (Figure
Figure 1. Indirect immunofluorescence on ethanol-fixed rat PMNs
with sera from Brown Norunay rats immunized with human MPO.
Magnification, X450.
1) and ELISA (Figure 2). The antibodies specifically
precipitated rat MPO from a crude extract prepared
from rat PECs (Figure 3). The same bands were
precipitated by a polyclonal antibody raised against
purified rat MPO that, in addition, recognizes smaller
MPO fragments. Sera from control immunized rats
were negative in all tests.
Urine Analysis
Control immunized rats receiving rabbit anti-GBM
antibodies developed moderate hematuria 10
days after injection (Figure 4). At earlier time
points, only intermediate hematuria was found in
some rats, the majority being negative. In contrast,
intermediate to severe hematuria developed in
hMPO-immunized animals starting at 24 hours af-
ter the anti-GBM antibody administration. Hematu-
ria increased in severity during the time period of
the experiment (Figure 4). Urine samples from rats
at day 10 still showed maximal hematuria after
10-fold dilution in physiological saline, illustrating
the extent of hematuria. In addition, low-grade pro-
teinuria was detectable 4 days after anti-GBM an-
tibody administration in both groups and had in-
creased at day 10 with a significantly higher
degree of proteinuria in hMPO-immunized rats as
compared with control rats (76.2 + 18.2 mg/24
hours versus 14.8 ± 8.1 mg/24 hours; Figure 5).
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Histopathology
Macroscopic Appearance of Kidneys
The macroscopic appearance of kidneys from
control immunized rats showed no abnormalities ex-
cept for occasional petechiae 10 days after the ad-
ministration of anti-GBM antibodies (Figure 6). How-
ever, kidneys from hMPO-immunized animals
showed some petechiae at 4 hours and widespread
petechiae at 24 hours and 4 and 10 days. In addi-
tion, kidneys at 10 days were swollen and had a pale
appearance (Figure 6).
Light Microscopy
In hMPO-immunized rats, a moderate influx of PMNs
was found at 4 hours. At 24 hours, a local influx of
PMNs and monocytes was observed in the glomeruli
of hMPO-immunized rats. In addition, in some glo-
30-,
21-
14>?.
Figure 3. Imnunoprecipitation studies nvith a cridcle cextract fromii -at
PEC cells. Broiun Norvay rats uwitb hMPO precipitated the character-
istic MPO bands at 58 and 38 kd (lanes A, B, and G). Conitrol
inimniunized rats dicd notprecipitate aiiyproteins(lanes C anid D). A
polyclonal rabbit anti-rat MPO also precipitated the 58- antd 38-kd
banzd but, in addition, also recognized sniallerbands (lane E). Normal
rabbit senimn did inot precipitate any¢! proteinis (lane F).
meruli capillaries showed thrombosis with hemosta-
sis and swelling of endothelial cells (Figure 7A).
These changes were less conspicuous in the control
immunized rats. At 4 days, the rats from the hMPO-
immunized group showed increased numbers of in-
tracapillary cells, mostly macrophages with endothe-
lial and mesangial proliferation and segmental
proliferation of epithelial cells in Bowman's space. At
10 days, the hMPO-immunized rats showed exten-
0
0fa
ci
0
._
I:
-
MPO
immunized
oontrol
Immunized
24 hours 4days 10 days
Figure 4. Occu{r^renice and seveerity qf heniatuia after anti-GBM ad-
ministration in conitrol aiid hMPO-imnninized rats. Residts represent
the mean bematuiza score at each tinie point. *rine samples from
hMPO-imnmzunized rats at day 10 after anti-GBM adminis.trationl di-
luated 10 times in physiological saline still showed maximal beniatuiria.
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Figure 5. Development ofproteinuria after anti-GBM administration
in control and hMPO-immunized rats. Results represent mean ± SD.
Iv < 0.02.
sive extracapillary proliferation with fibrinoid necrosis
of capillary walls, extravasation of erythrocytes, and
in some glomeruli destruction of Bowman's capsule
with formation of multinucleated giant cells. Crescent
formation was found in 24 to 60% of the glomeruli
(mean, 41.2%; n = 5). In most kidneys, extensive
interstitial inflammatory changes were observed at
this time (Figure 7, D-F). At 10 days after anti-GBM
IgG administration, the kidneys of control immunized
rats showed only mild intracapillary proliferation as
shown in Figure 7B. Severe lesions, such as the
development of crescents, the occurrence of inter-
stitial infiltrates and tubular atrophy, and necrosis
were not observed.
4 hours 24 hours
Immunophenotyping
Phenotypic analysis of intraglomerular inflammatory
cells in control immunized rats showed a slight influx
of PMNs (1.3 ± 0.3 per glomerulus) at 4 hours after
anti-GBM administration (see Table 2). At later time
points, the predominant infiltrating cells were ED1 +
macrophages, which peaked at day 4. No intraglo-
merular T cells were found at any time (Table 1). In
addition, interstitial macrophages were only occa-
sionally found at day 10 (Table 1). Rats immunized
with hMPO also showed an influx of PMNs (1.9 + 0.4
per glomerulus) at 4 hours and ED1 + macrophages
at 24 hours and 4 and 10 days after anti-GBM ad-
ministration (Table 1). The total number of infiltrating
inflammatory cells was generally higher compared
with control immunized rats. Occasionally, some T
cells were observed at day 10 (Table 1). In addition,
at 10 days, large numbers of inflammatory cells ac-
cumulated in the interstitium mainly consisting of
ED1+ macrophages (Table 1).
Immunofluorescence
Immunofluorescence studies showed strong linear
deposition of rabbit IgG along the glomerular capil-
lary wall at all time points in both experimental
groups (Figure 8 and Table 2). Complement C3 was
only weakly present whereas no linear deposition of
rat IgG was found along the capillary walls of either
4 days 10 days
MPO
immunized
Control
immunized
I_
Figure 6. Macroscopic appearance of kidneys from control or hMPO-immunized Brown Noruvay rats 4 hours, 24 hours, 4 day.s, and 10 days after
administration ofa subnephritogenic dose ofanti-GBM antibodies. Widespreadpetechiae are seen in kidnevsfrom hMPO-inimmun ized rats at 24 hours-
and 4 and 10 days. In addition, kidneys at 10 days after anti-GBM administration appear suollen. Bar, 2 cmt.
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Figure 7. Light microscopy. A: Light micrograph showing a glomerulus at 24 hours after injection ofanti-GBM IgG in a MPO-immunized rat showing
deposition offibrin and stasis oferythrocytes. Methenamine silver; magnification, X 250. B: Light micrograph showing a glomerulus at 10 days after
injection ofanti-GBM IgG in a control immunized rat. Local intracapillary accumulation of macrophages is obsered. Methenamine silver; X360.
C to F: Ligbt micrographs showing glomeruli at 10 days after injection of anti-GBM IgG in MPO-immunized rats. Intra- and extracapillary
proliferation, crescent formation, extravasation of erythrocytes into Bowman's space, multinucleated giant cells, and extensive interstitial inflam-
mation can be seen. Methenamine silver (C to E) and periodic acid-Schiff (F); magnification, x360.
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Table 1. Intraglomerular and Interstitial Presence of Macrophages, PMNs, and T Cells
Infiltrating Intraglomerular cells Interstitial cells
cells Groups 4 hours 24 hours 4 days 10 days 4 hours 24 hours 4 days 10 days
PMNs 1.9 ± 0.4 1.4 0.4 0.78 + 0.1 1.2 ± 0.2 0 0 0.8 ± 0.4 2.2 ± 0.4
11 1.3 ± 0.3 1.0 0.3 0.72 0.3 0.7 ± 0.1 0 0 0 0.3 ± 0.2
Monocytes 1.1 ± 0.1 2.7 + 0.7 7.0 ± 1.6 6.9 + 1.5* 0 0 1.4 ± 0.2 3.2 ± 0.2
11 0.7 -+ 0.1 2.5 1.3 6.0 ±2.7 3.7 ± 0.5 0 0 0.3 ± 0.3 0.5 ± 0.3
T cells 0 0 0 0.2 t 0.1 0 0 0 0.5 ± 0.3
11 0 0 0 0 0 0 0 0
In group 1, rats were immunized with hMPO. In group 11 were control immunized rats. The number of intraglomerular PMNs, monocytes,
and T cells was estimated by counting positive cells in 50 glomeruli and dividing the total by 50. Numbers represent mean ± SD. Labeled
interstitial cells were scored on a semiquantitative scale: 0, absent; 1, minimal; 2, mild; 3, moderate; 4, severe. Results represent mean
scores + SEM.
*P < 0.05.
group at any time (Figure 8). However, complement
and rat IgG were detected in Bowman's space in
conjunction with fibrinoid necrosis and cellular cres-
cents at day 10 in hMPO-immunized rats (Figure 8).
Until day 4, deposition of fibrin showed a similar
pattern and extent in both groups. No deposition of
fibrin was found at 4 hours whereas weak diffuse
deposition was seen at 24 hours (Figure 9). At day 4,
30 to 50% of the glomeruli showed focal and seg-
mental glomerular deposition of fibrin. At 10 days
after anti-GBM administration, a significant differ-
ence in glomerular fibrin score was found between
both experimental groups (Figure 9). In hMPO-immu-
nized rats, fibrin deposition had increased in inten-
sity, involving most glomeruli. At this time, fibrin dep-
osition was also found in Bowman's space, within
crescents, and in tubular lumens (Figures 8 and 9).
In contrast, the pattern and extent of fibrin deposition
in control immunized rats was not significantly differ-
ent from that found at day 4 (Figure 9).
Glomerular Presence of Rat MPO
Staining for rat MPO showed strong intracellular
staining of infiltrating leukocytes at 4 and 24 hours
after anti-GBM administration in both groups (Figure
10A). In addition, extracellular granular staining of rat
MPO was observed (Figure 10, B and C), although
not all rat-MPO-positive cells were accompanied by
extracellular staining. No apparent difference in the
amount of extracellular staining was noted between
hMPO-immunized and control immunized rats. At 4
and 10 days after anti-GBM administration, only
weak staining for rat MPO was found in both groups.
Discussion
In the present study, rats immunized with hMPO
developed antibodies to hMPO that cross-reacted
with rat MPO. When, subsequently, these rats were
challenged with a subnephritogenic dose of rabbit
anti-rat GBM antibodies, severe glomerulonephritis
developed. Clinically, the glomerulonephritis was
characterized by the early onset of severe hematuria
and exacerbation of proteinuria while histopatholog-
ically crescent formation, tuft necrosis, and tubulo-
interstitial nephritis were observed. In contrast, con-
trol immunized rats receiving the same amount of
rabbit anti-rat GBM antibodies showed only mild glo-
merulonephritis. These results demonstrate a patho-
genic role of the anti-rat MPO autoantibodies in the
development of crescentic glomerulonephritis in this
experimental model.
Several other in vivo observations have pointed
toward a pathogenic role for ANCAs. Anti-MPO an-
tibodies have been demonstrated in sera from mer-
cury-chloride-treated Brown Norway rats and in a
mouse strain with spontaneous NCGN developed by
genetic selection from lupus prone MRL mice.2630
Interestingly, in both models, vasculitis has been
observed. However, the immune response to MPO is
part of a polyclonal B-cell stimulation in both models,
which makes the specific pathophysiological role of
anti-MPO antibodies in the induction of vasculitis
difficult to interpret. The studies presented here are
based on the hypothesis that focal neutrophil activa-
tion by circulating autoantibodies to MPO leads to
the development of anti-MPO-associated crescentic
glomerulonephritis. As has been reported previ-
Figure 8. Localization of rabbit IgG, rat IgG, complement, and fibrin by immunofluorescence. A and B: Linear staining along the glomerular
capillary wall of rabbit IgG 24 hours after anti-GBM administration in control (A) and bMPO-immunized (B) rats. C: Absence of linear deposition
of rat IgG in glomeruli from a hMPO-immunized rat 10 days after anti-GBM administration. D: Strong staining of complement alotng Bowman's
capsule in a hMPO-immunized rat 10 days after anti-GBM administration. E: Moderate fibnin deposition in glomemulifrom a control immunized
rat 10 days after anti-GBM administration. F: Massive glomerularfibrin deposition in a hMPO-immunized rat 10 days after anti-GBM adminis-
tration. Magnificatiotn, X250 (A and B) and x360 (C to F).
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Table 2. Intraglomernlar Presence of Rabbit IgG, rat IgG, and C'omplement
Rabbit IgG
4 24 4
Groups hours hours days
Rat IgG
10 4 24 4 10 4
days hours hours days days hours
Complement
24 4 10
hours days days
4 4 4 3.6 ± 0.2 0
11 4 4 4 4 0
0 1.6 + 0.4 1.8 + 0.4 0.5 ± 0.3 0.5 + 0.3 1.6 ± 0.2 2.4 + 0 3
0 1.5 ± 0.3 1.3 + 0.3 0.3 ± 0.3 0.5 + 0.3 1.0 + 0.5 1.5 + 0.3
In group 1, rats were immunized with hMPO. In group 11 were control immunized rats. The presence of rabbit IgG, rat IgG, and
complement was scored on a semiquantitative scale: 0, absent; 1, weak; 2, mild; 3, intermediate; 4, strong. Results represent mean
scores + SEM.
ously, the development of anti-MPO antibodies after
immunization is in itself not sufficient to induce any
lesions.1831 In addition, in vitro studies have shown
that ANCAs stimulate human PMNs to produce re-
active oxygen metabolites and enhance degranula-
tion only after cytokine priming of PMNs.10 In our
model, the induction of a mild anti-GBM nephritis
possibly served as the priming process. Administra-
tion of a subnephritogenic dose of anti-GBM results
in a mild PMN influx and complement activation.32 In
the presence of MPO autoantibodies, this may result
in the development of severe NCGN. The exact
mechanisms by which the autoantibodies to MPO
aggravate mild anti-GBM nephritis are not clear, but
several possibilities may be considered.
First, in vitro studies have shown that anti-GBM/
GBM immune complexes as well as anti-MPO anti-
bodies can induce MPO release from PMNs, and
both mechanisms may be relevant in the model pre-
sented here.1033 Indeed, rat MPO was found in an
extracellular localization in glomerular capillary
structures. MPO is a highly cationic enzyme that,
upon exocytosis or degranulation, will bind to nega-
tively charged structures such as the GBM or endo-
thelial cells. Active MPO reacts with H202 and ha-
lides to form reactive oxygen metabolites that induce
acute glomerular injury.34-36 Once MPO is released
from the cell, MPO/anti-MPO complexes may form,
leading to prolonged presence of the active enzyme
and more extensive morphological damage.
Second, the development of focal MPO/anti-MPO
immune complexes may also enhance the influx of
inflammatory cells resulting in an increased produc-
tion of reactive oxygen radicals and release of pro-
I
T T
24 hours 4 days 10 days
Figure 9. Glomenldarfibniin deposition at 24 houirs- and 4 anld 10 days
after aniti-GBM administration in control and hMPO-inimunized rats.
Fibrinl deposition was scored semiquantitatiwely according to thefol-
lowing scale. 0, absent; 1, less thani 25%; 2. between 25 and 50%; 3,
betwveen 50 atnd 750Yo, anid 4, betiveen 75 anid 100% of the total
glomedriilar area. Reslults are expressed as motean score + lSD. 'i < 0. 02.
MPO
immunized
control
immunized
Figure 10. Localization of rat MPO in glomeruli from bMPO-imnmui-
nized rats 24 hour.s after anti-GBM administration by indirect imino-
nofluorescence. A: Intracellular localizationl of rat MPO. B: Intracel-
Ilular staining acconmpanied by extracellular graniular staining of rat
MPo. C: EIrtracellular staininX,g of rat MVPO (arrow). Mlagnyiication,
x 360.
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teolytic enzymes. However, it should be stressed
that we found no abnormal quantities of rat IgG in the
glomeruli. The role of focal immune complex forma-
tion in anti-MPO-associated NCGN was also tested
by Brouwer et al.18 They developed an animal model
in which a human neutrophil lysosomal extract con-
sisting of MPO and trace amounts of proteinase 3
and elastase and H202 were perfused into the kid-
ney of Brown Norway rats previously immunized with
hMPO. These rats developed a NCGN characterized
by intra- and extracapillary proliferation, ruptured
Bowman's capsule, periglomerular granulomatous
inflammation, and formation of giant cells while IgG
and C3 were scanty or absent. This model therefore
closely resembles the human disease of ANCA-as-
sociated NCGN, although some controversy exists
on the pauci-immune character of this model.31 In
line with these observations are the data of Koba-
yashi et al,37 who described exacerbation of anti-
GBM disease in the rat by heterologous anti-rat MPO
antibodies. They showed that the administration of
rabbit anti-rat MPO together with anti-GBM antibod-
ies increases fibrin accumulation and the number of
infiltrating PMNs 3 and 15 hours after injection, al-
though neither crescent formation or tuft necrosis
was seen. In addition, deposition of rat MPO along
the GBM was found, and anti-MPO antibodies could
be eluted from the kidney. These results suggest that
focal MPO/anti-MPO immune complex formation is
responsible for the aggravation of the anti-GBM ne-
phritis. However, this model is based on heterolo-
gous anti-MPO antibodies and therefore cannot be
regarded as a genuine autoimmune model for
ANCA-associated glomerulonephritis.
Third, recent studies have shown that anti-MPO
antibodies enhance cytokine production by
PMNs.13,38 Cytokines, like tumor necrosis factor-a
and interleukin-1, aggravate mild anti-GBM nephritis
when administered systemically.38'39 In addition, it
was shown that, in patients with active Wegener's
disease as well as in sepsis patients, monocytes
express MPO on their cell surface, and it has been
reported that ANCAs induce monocyte chemoattrac-
tant protein-1 production by monocytes.40A41 There-
fore, increased cytokine production by monocytes
and PMNs due to interaction with anti-MPO antibod-
ies could be an alternative mechanism in our model
and should be studied further.
In conclusion, these studies demonstrate that au-
toantibodies to MPO markedly aggravate mild anti-
GBM disease and suggest that ANCAs may be a
pathogenic factor in rendering mild glomerular injury
into clinically overt disease.
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